News Archive

DCRI faculty recently contributed to a paper advocating for a focus on pain management so that progress in combatting the U.S. opioid crisis is not lost in the midst of the COVID-19 pandemic.

Study results recently published in the Journal of the American College of Cardiology: Heart Failure build on novel research investigating the efficacy of blocking the splanchnic nerve to treat patients with heart failure. The study, which was led by former DCRI fellow Marat Fudim, MD, MHS, included 15 patients who underwent a temporary medication-induced splanchnic nerve blockage and required them to complete an exercise twice—once prior to the blockage, and once after the blockage.

Although valve failure is rare, patients who had to undergo re-operation were at risk of negative outcomes.

The DCRI’s Eric Peterson, MD, MHS, recently reviewed an important study in JAMA examining novel strategies to de-escalate hypertension treatment in older adults.

The FDA recently made a precedent-setting decision—for the first time, a video game can be marketed and prescribed as a therapeutic. EndeavorRx, a digital therapeutic created by Akili Interactive Labs, is a video game designed to improve attention in children ages 8 to 12 who have been diagnosed with attention-deficit hyperactivity disorder (ADHD).

Two DCRI fellows, one former and one current, recently contributed to a paper published in Journal of the American Medical Informatics Association on the role telehealth has played in U.S. health care during the COVID-19 pandemic. The paper, for which DCRI cardiology fellow Jedrek Wosik, MD, is the corresponding author, details how telehealth has transformed both within the Duke Health system and beyond through the collaboration of people, processes, and technology. The paper focuses on three distinct phases of the crisis caused by the novel coronavirus: outpatient care during the stay-at-home orders, the initial COVID-19 hospital surge, and recovery post-pandemic.

The study team used pediatric patients’ electronic health records to identify patients eligible for the study.

The registry, which has enrolled 1,002 patients with idiopathic pulmonary fibrosis, shares critical knowledge and insights to help combat lung disease.

Data provided to the FDA by the research network has helped to provide a fuller picture for prescribing these medications to pediatric populations.

A pragmatic comparative effectiveness study comparing Micra leadless pacemakers to conventional transvenous pacemakers found that for patients who received the novel leadless pacemakers, complicati